Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests begin for new weight and diabetes drug

NCT ID NCT06945419

Summary

This is an early-stage study to check the safety and how the body processes a new drug called LY4086940. It will involve healthy people and people who are overweight, have obesity, or have type 2 diabetes. The main goal is to see how well the drug is tolerated and to measure its levels in the blood.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Pharmacology of Miami

    NOT_YET_RECRUITING

    Miami, Florida, 33172, United States

    Contact Phone: •••-•••-••••

    Contact

  • Endeavor Clinical Trials

    RECRUITING

    San Antonio, Texas, 78240, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit

    RECRUITING

    Daytona Beach, Florida, 32117, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit

    RECRUITING

    Dallas, Texas, 75247, United States

    Contact Phone: •••-•••-••••

    Contact

  • Lilly Centre for Clinical Pharmacology

    COMPLETED

    Singapore, 138623, Singapore

Conditions

Explore the condition pages connected to this study.